Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2561)	8/13/2009 12:27:26 PM
From: Jibacoa	Respond to of 3722

ACAD continues its near term UT that started on May 4 from the $1 level.<g> Today it is still trading above its Aug11 H at $5.63 bigcharts.marketwatch.com It reported last week its 2ndQ results, which showed a loss of $12.7M ($0.34/shr) vs. a loss of $18.3M ($0.49/shr) in 2008. For the six months, it reported a loss of $27.7M ($0.75/shr)vs. $34.7M ($0.94/shr). Its reported cash of $66.2M vs. $60.1M in Dec2008.(It received a $39M payment from its collaboration with BVF. The increase in cash was primarily due to an upfront cash payment of $30 million received in May 2009 pursuant to ACAD’s collaboration with BVF.) ACAD has a PII of pimavanserin for patients with PD’s psychosis. <g> It also has other drugs on its pipeline for treatment of CNS disorders. Revenues were much better, showing a 911% improvement.($1.8M vs.$177,000). If the stock can close its Jun2008 DG it could test the $8 level.<g> bigcharts.marketwatch.com Bernard